Exploration of vanoxerine analogues as antibacterial agents

Alexander D. H. Kingdon,Holly V. Adcock,Eleni-Marina Kasimati,Philip Craven,Willem van Schaik,Liam R. Cox,Gurdyal S. Besra
DOI: https://doi.org/10.1038/s41429-024-00781-9
2024-10-16
The Journal of Antibiotics
Abstract:Mycobacterium tuberculosis is a bacterial pathogen, responsible for approximately 1.3 million deaths in 2022 through tuberculosis infections. The complex treatment regimen required to treat tuberculosis and growing rates of drug resistance, necessitates the development of new anti-mycobacterial agents. One approach is to repurpose drugs from other clinical applications. Vanoxerine (GBR 12909) was previously shown to have anti-mycobacterial activity, through dissipating the membrane electric potential and hence, cellular energetics. Several vanoxerine analogues were synthesised in this study, which exhibited a range of activities against mycobacteria and enterococcus. All active analogues had similar impacts on the membrane electric potential and inhibition of ethidium bromide efflux. The most active compound displayed reduced inhibitory activity against the known human target of vanoxerine, the dopamine transporter. This work has identified a promising analogue, which could provide a starting point for further medicinal chemistry and drug development efforts to target mycobacteria.
pharmacology & pharmacy,immunology,biotechnology & applied microbiology,microbiology
What problem does this paper attempt to address?